CDK4/6 inhibitors in luminal breast cancer
Mené sur 165 patientes atteintes d'un cancer avancé du sein HER2-, ER+ après la ménopause, cet essai de phase II évalue l'efficacité, du point de vue de la survie sans progression, et la toxicité de l'ajout du palbociclib au létrozole en traitement de première ligne
Endocrine therapy in steroid-receptor positive, luminal breast cancer is often regarded as a prototype of biologically targeted treatment and yet, by contrast with HER2-overexpressing disease, pathway-directed breakthrough innovations have been rare in this subtype. Although reliable identification of steroid receptors and the introduction of tamoxifen and aromatase inhibitors resulted in major improvements in outcomes for patients with early stage breast cancer, many patients will eventually relapse, suggesting resistance to endocrine therapy.
The Lancet Oncology , commentaire, 2013